What do large scale studies of medication in schizophrenia add to our management strategies?

Psychiatria Danubina

Volumn 22, Issue 2, 2010, Pages 323-328

  Agius, Mark ^a,c   Davis, Abigail ^b   Gilhooley, Michael ^b   Chapman, Shelley ^b   Zaman, Rashid ^a,c  

^a South Essex Partnership University Foundation Trust ^*  (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Anti psychotics; Effectiveness; Efficacy; First episode psychosis; Recovery; Schizophrenia

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; COST UTILITY ANALYSIS; DROWSINESS; DRUG COST; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE METABOLISM; HUMAN; INSOMNIA; LIPID METABOLISM; MEDLINE; MENSTRUAL IRREGULARITY; METABOLIC DISORDER; OUTCOME ASSESSMENT; OUTPATIENT; PRACTICE GUIDELINE; PSYCHOSIS; QUALITY OF LIFE; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SLEEP TIME; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG COSTS; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77954380287     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Agius M & Zaman R: Some Issues with Cutlass British Journal of Psychiatry Electronic Letters 17 March 2008.
2. Gasquet I, Haro JM, Tcherny-Lessenot S, Chartier F & Lépine JP: Remission in the outpatient care of schizophrenia: 3-year results from the Schizophrenia Outpatients Health Outcomes (SOHO) study in France. Eur Psychiatry. 2008; 23:491-6.
3. Haro JM, Novick D, Suarez D & Roca M: Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. J Psychiatr Res. 2009 ;43:265-73.
4. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A & Lewis SW: Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006; 63:1079-87
5. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A & Grobbee DE; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008 ;371(9618):1085-97.
6. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J & Hsiao JK: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 22;353:1209-23.
7. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P & Strakowski SD: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1050-60.
8. Novick D, Haro JM, Suarez D, Vieta E & Naber D: Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009; 108:223-30.
9. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM & Lieberman JA: Comparison of Atypicals in First Episode study group Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008; 69:106-13.
10. Suarez D & Haro JM: Overview of the findings from the European SOHO study Expert Rev Neurother. 2008; 8:873-80.